The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
International phase 2 clinical trial comparing the effect of neoadjuvant PF-07220060 plus letrozole versus letrozole alone on Ki-67 tumor expression in postmenopausal women with HR+/HER2− breast cancer
Shom Goel, Khalil Zaman, Seock-Ah Im, Ahmed Elkhanany, Chiun-Sheng Huang, Cristian Villanueva, Sara Lopez Tarruella, Chin-Hee Chung, Ann Alcasid,Yuan Liu, ,Cynthia Basu, Michail Ignatiadis
Atirmociclib (PF-07220060) | December 13, 2024 | SABCS 2024
C4391025 | NCT06465368
Presentation
PHASE 1B/2 FIRST-IN-CLASS NOVEL COMBINATION TRIAL OF NEXT GENERATION CDK4-SELECTIVE INHIBITOR PF-07220060 AND NEXT GENERATION CDK2-SELECTIVE INHIBITOR PF-07104091 IN HR+ HER2- METASTATIC BREAST CANCER AND ADVANCED SOLID TUMORS
Yap T, Yan F, Sadeghi S, Lin T, Liu F, Malky L, Golmakani M, Moreau A, Neumann H, Zhou L, Juric D, Sharma M
Tegtociclib (PF-07104091) + Atirmociclib (PF-07220060) | September 13, 2024 | ESMO 2024
C4391002 | NCT05262400